Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
4.56M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
115K
-
Shares change
-
-254K
-
Total reported value, excl. options
-
$1.16M
-
Value change
-
-$1.94M
-
Number of sells
-
-2
-
Price
-
$10.24
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) as of Q4 2023
3 filings reported holding RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q4 2023.
RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 115K shares
of 4.56M outstanding shares and own 2.52% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (24.2M shares), ARK Investment Management LLC (20.7M shares), VANGUARD GROUP INC (15.7M shares), Mubadala Investment Co PJSC (13M shares), BlackRock Inc. (12.4M shares), STATE STREET CORP (12.2M shares), FMR LLC (10.9M shares), Kinnevik AB (publ) (10.4M shares), Nikko Asset Management Americas, Inc. (9.2M shares), and Sumitomo Mitsui Trust Holdings, Inc. (9.2M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.